Compare ELTX & BARK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELTX | BARK |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Department/Specialty Retail Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.2M | 92.7M |
| IPO Year | 2014 | 2020 |
| Metric | ELTX | BARK |
|---|---|---|
| Price | $3.04 | $10.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $18.00 | ★ $37.50 |
| AVG Volume (30 Days) | ★ 269.9K | 51.7K |
| Earning Date | 05-12-2026 | 06-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.29 | N/A |
| EPS | N/A | ★ 0.08 |
| Revenue | $2,301,000.00 | ★ $394,843,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.43 |
| P/E Ratio | ★ N/A | $130.13 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.66 | $0.50 |
| 52 Week High | $16.00 | $11.32 |
| Indicator | ELTX | BARK |
|---|---|---|
| Relative Strength Index (RSI) | 41.08 | 52.10 |
| Support Level | $2.72 | $8.49 |
| Resistance Level | $3.28 | $10.94 |
| Average True Range (ATR) | 0.17 | 0.61 |
| MACD | 0.12 | 0.02 |
| Stochastic Oscillator | 51.24 | 44.00 |
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
BARK Inc is a vertically integrated, omnichannel brand serving dogs across two key categories: toys & accessories and consumables. It serves dogs nationwide with monthly subscription services, BarkBox and Super Chewer; e-commerce experience on BarkShop.com; custom collections via its retail partner network, including Target and Amazon; wellness products that meet dogs' needs with BARK Bright; and a personalized meal delivery service for dogs BARK Eats. The company's reportable segments are; Direct to Consumer (D2C), and Commerce. The majority of its revenue is generated from the Direct to Consumer segment which derives revenue from the sale of toys & accessories and consumables through BarkBox, Super Chewer, and the company's consumables website.